RELMADA THERAPEUTICS INC (RLMD)

US75955J4022 - Common Stock

3.76  +0.08 (+2.17%)

Unregistered users can only see 4 years or quarters

Examples of complete financials are available for MSFT and AAPL.

Please register or login for additional data.

2023
(2023-12-31)
2022
(2022-12-31)
2021
(2021-12-31)
2020
(2020-12-31)
2019
(2019-6-30)
Revenue
0.000.000.000.000.00
Operating Expenses
103.70M161.25M125.70M60.84M12.73M
Research and Development
54.81M113.32M90.62M35.97M7.02M
Selling, General, and Administrative Expenses
48.89M47.93M35.08M24.87M5.70M
Operating Income
-103.70M-161.25M-125.70M-60.84M-12.73M
Interest Income/Expense
4.91M-2.15M-50.00K1.38M-820.00K
Other Income/Expense
0.006.35MN/AN/A0.00
Non Recurring Items
N/AN/AN/AN/A-3.77M
Income Before Taxes
-98.79M-157.04M-125.75M-59.46M-17.32M
Income Tax
N/AN/AN/AN/AN/A
Net Income
-98.79M-157.04M-125.75M-59.46M-17.32M
EBITDA
N/AN/AN/AN/AN/A
 
Per Share Data
EPS Diluted Total Ops
-3.28-5.30-7.16-3.81-2.74
Non GAAP EPS
-3.28-5.45-7.14N/AN/A
 
Statistics

All data in USD

Charts